The culture of tissue-derived human cells is an important aspect of tissue engineering. Prior to transplantation, the quality of the cultured cells/tissue should be routinely tested so that any enrichment of procarcinogenic cells can be excluded. On this account, a UVB-induced p53 fingerprint mutation would be a valuable quality control marker for skin cells cultured for use in tissue engineering. We developed an allele-specific real-time polymerase chain reaction assay based on SYBR Green which can quantitatively detect CC-TT transitions in the tumor suppressor gene p53. To analyze the transition 281/282, we used DNA from HaCaT cells, a keratinocyte cell line containing the investigated mutation, as a standard to determine the mutation frequency in cultured cutaneous cells. We analyzed a variety of skin cells grown in culture and found a notable decrease in the UVB fingerprint mutation in fibroblasts during proliferation. Furthermore, we quantified the total amount of mutated DNA in different cutaneous cells and detected a significantly higher level in melanocytes. These results are consistent with findings obtained in our laboratory concerning the common deletion, the most frequently reported mutation in the mitochondrial genome, which suggest a positive influence of prolonged in vitro cell proliferation on the quality of genomic DNA.

1.
Ablett, E., J. Pedley, P.A. Dannoy, R.A. Sturm, P.G. Parsons (1998) UVB-specific regulation of gene expression in human melanocytic cells: cell cycle effects and implication in the generation of melanoma. Mutat Res 422: 31–41.
2.
Boehm, D., S. Herold, A. Kuechler, T. Liehr, F. Laccone (2004) Rapid detection of subtelomeric deletion/duplication by novel real-time quantitative PCR using SYBR-green dye. Hum Mutat 23: 368–378.
3.
Brash, D.E., J.A. Rudolph, J.A. Simon, A. Lin, G.J. McKenna, H.P. Baden, A.J. Halperin, J. Ponten (1991) A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88: 10124–10128.
4.
Chan, W.M., W.Y. Siu, A. Lau, R.Y. Poon (2004) How many mutant p53 molecules are needed to inactivate a tetramer? Mol Cell Biol 24: 3536–3551.
5.
Fayolle, C., J. Pourchet, A. Cohen, R. Pedeux, A. Puisieux, C.C. de Fromentel, J.F. Dore, T. Voeltzel (2006) UVB-induced G2 arrest of human melanocytes involves Cdc2 sequestration by Gadd45a in nuclear speckles. Cell Cycle 5: 1859–1864.
6.
Fernandez, F., J. Gutierrez, A. Sorlozano, J.M. Romero, M.J. Soto, F. Ruiz-Cabello (2006) Comparison of the SYBR Green and the hybridization probe format for real-time PCR detection of HHV-6. Microbiol Res 161: 158–163.
7.
Francino, O., L. Altet, E. Sanchez-Robert, A. Rodriguez, L. Solano-Gallego, J. Alberola, L. Ferrer, A. Sanchez, X. Roura (2006) Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis. Vet Parasitol 137: 214–221.
8.
Gailani, M.R., D.J. Leffell, A. Ziegler, E.G. Gross, D.E. Brash, A.E. Bale (1996) Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. J Natl Cancer Inst 88: 349–354.
9.
Harris, C.C. (1993) p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262: 1980–1981.
10.
Hussein, M.R. (2004) The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship? Tumor Biol 25: 200–207.
11.
Ishii, H.H., G.C. Gobe, J. Yoneyama, M. Mukaide, Y. Ebihara (2004) Role of p53, apoptosis, and cell proliferation in early stage Epstein-Barr virus positive and negative gastric carcinomas. J Clin Pathol 57: 1306–1311.
12.
Kadekaro, A.L., R.J. Kavanagh, K. Wakamatsu, S. Ito, M.A. Pipitone, Z.A. Abdel-Malek (2003) Cutaneous photobiology. The melanocyte vs the sun: who will win the final round? Pigment Cell Res 16: 434–447.
13.
Koch, H., K.P. Wittern, J. Bergemann (2001) In human keratinocytes the common deletion reflects donor variabilities rather than chronologic aging and can be induced by ultraviolet A irradiation. J Invest Dermatol 117: 892–897.
14.
Korkolopoulou, P., P. Christodoulou, P. Kapralos, M. Exarchakos, A. Bisbiroula, M. Hadjiyannakis, C. Georgountzos, E. Thomas-Tsagli (1997) The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Pract 193: 767–775.
15.
Li, W., A. Sanki, R.Z. Karim, J.F. Thompson, C. Soon Lee, L. Zhuang, S.W. McCarthy, R.A. Scolyer (2006) The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 38: 287–301.
16.
Milner, J. (1991) The role of p53 in the normal control of cell proliferation. Curr Opin Cell Biol 3: 282–286.
17.
Olivier, M., R. Eeles, M. Hollstein, M.A. Khan, C.C. Harris, P. Hainaut (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607–614.
18.
Rodriguez, H., C. O’Connell, P.E. Barker, D.H. Atha, P. Jaruga, M. Birincioglu, M. Marino, P. McAndrew, M. Dizdaroglu (2004) Measurement of DNA biomarkers for the safety of tissue-engineered medical products, using artificial skin as a model. Tissue Eng 10: 1332–1345.
19.
Siefken, W., U. Hoppe, J. Bergemann (1999) Semiquantitative chemiluminescent detection of UV-B-induced point mutations in the p53 tumor-suppressor gene. Biotechniques 26: 528–530.
20.
Szoke, D., F. Sipos, S. Spisak, B. Molnar, Z. Tulassay (2005) The p53 gene and protein in 2005: new results, promising opportunities. Orv Hetil 146: 1587–1594.
21.
Tanaka, K., S. Kamiuchi, Y. Ren, R. Yonemasu, M. Ichikawa, H. Murai, M. Yoshino, S. Takeuchi, M. Saijo, Y. Nakatsu, H. Miyauchi-Hashimoto, T. Horio (2001) UV-induced skin carcinogenesis in xeroderma pigmentosum group A (XPA) gene-knockout mice with nucleotide excision repair-deficiency. Mutat Res 477: 31–40.
22.
Zinkel, S., A. Gross, E. Yang (2006) BCL2 family in DNA damage and cell cycle control. Cell Death Differ 13: 1351–1359.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.